<DOC>
	<DOCNO>NCT01391130</DOCNO>
	<brief_summary>To compare progression free survival LY2510924 plus sunitinib therapy versus sunitinib first-line setting patient metastatic clear-cell renal cell carcinoma .</brief_summary>
	<brief_title>A Study LY2510924 Sunitinib Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Evidence histologically confirm renal cell carcinoma ( RCC ) metastases component clear ( conventional ) cell histology A diagnosis metastatic renal cell carcinoma ( RCC ) receive prior treatment systemic ( adjuvant neoadjuvant ) therapy renal cell carcinoma ( RCC ) ( include target therapy tyrosine kinase inhibitor bevacizumab , immunotherapy , chemotherapy , hormonal , investigational therapy ) Evidence measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Computed tomography ( CT ) magnetic resonance imaging ( MRI ) perform within 4 week prior study entry Participants primary tumor remove nephrectomy allow . Participants nephrectomy consider need nephrectomy part overall therapy time enrollment Performance status score 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Adequate bone marrow , liver , renal function , assess follow laboratory requirement , conduct within seven day prior treatment : ( upper limit normal/lower limit normal [ ULN/LLN ] ) hemoglobin ( great ) &gt; 8.0 g/dL ( grams per deciliter ) absolute neutrophil count ( ANC ) ( great equal ) ≥1.5 × 10^9/L ( liter ) platelet count ( great equal ) ≥100 × 10^9/L ( liter ) total bilirubin ( less equal ) ≤ 1.5 × ULN ( upper limit normal ) serum creatinine ( less equal ) ≤2 × ULN ( upper limit normal ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ( less equal ) ≤2.5 × ULN ( upper limit normal ) [ ( less equal ) ≤5 × ULN ( upper limit normal ) patient liver involvement cancer ] Prothrombin Time ( PT ) International Normalized Ratio ( INR ) activate Partial Thromboplastin Time ( aPTT ) ( less equal ) ≤1.5 x ULN ( upper limit normal ) For woman : Must surgically sterile ( surgical procedure : bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) , postmenopausal ( least 12 consecutive month amenorrhea ) , negative pregnancy test . Women childbearing potential compliant medically approve contraceptive regimen ( intrauterine device [ IUD ] , birth control pill , barrier device ) 3 month treatment period ; must negative serum pregnancy test within 7 day study enrollment , must breastfeed For men : Must surgically sterile compliant contraceptive regimen 3 month treatment period Estimated life expectancy least 12 week Provide write informed consent/assent prior studyspecific procedure No prior malignancy exception stage 1 cancer definitively treat , carcinoma situ ( primary site ) , treat nonmelanoma skin cancer , superficial bladder tumor ( Ta , Tis , T1 ) cancer curatively treat 5 year prior study entry Capable willing learn selfadminister LY2510924 , caregiver willing learn able administer LY2510924 subcutaneous ( SC ) injection able swallow tablet Left ventricular ejection fraction ( LVEF ) great equal LLN define institution perform scan , assessed Multiple Gated Acquisition ( MUGA ) scan , echocardiogram perform within 28 day prior start treatment Received prior treatment sunitinib LY2510924 Received treatment within last 30 day drug receive regulatory approval indication time study entry History active cardiovascular disease within previous 12 month , include follow : Myocardial infarction Unstable angina Coronary artery/peripheral artery bypass graft Congestive heart failure Malignant hypertension Cerebrovascular accident transient ischemic attack Symptomatic cardiac arrhythmia ( Patients chronic , stable , rate control atrial fibrillation eligible ) Exhibit uncontrolled hypertension ( [ great ] &gt; 150/100 [ millimeter mercury ] mm/Hg despite optimal medical therapy ) , history poor compliance antihypertensive treatment Evidence bleeding diathesis , National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Grade 3 hemorrhage ( less ) &lt; 4 week start study treatment , coagulopathy , thromboembolic event Significant surgery ( less ) &lt; 4 week start study treatment minor surgical procedure ( less ) &lt; 7 day prior study treatment ( Placement portacath venous access device require wait period ) Suffer medical , psychological , social condition may interfere patient 's participation study evaluation study result Known suspect allergy agent give association trial Prior palliative radiotherapy metastatic lesion ( ) is/are permit , provide least 1 measurable lesion irradiate . Radiotherapy must complete ( great ) &gt; 2 week prior start study treatment , radiationrelated side effect must resolve Pregnant lactate woman Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption sunitinib Current recent ( within 10 day first dose study treatment ) daily use aspirin ( [ great ] &gt; 325 [ milligram ] mg/day ) Serious nonhealing wound , acute nonhealing ulcer , bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Metastasis</keyword>
</DOC>